IGF-1 stands for insulin-like growth factor 1. It is a signaling protein involved in growth and tissue regulation and is closely connected to the growth-hormone system. The name reflects structural relationships, but IGF-1 is not interchangeable with insulin.

Part of a wider network

GH stimulates IGF-1 production in the liver and other tissues. IGF-1 then participates in growth-related effects and feedback regulation. Circulating measurements provide one view of this system, but local production and binding proteins also influence biological activity.

IGF-1 concentrations vary across the lifespan. Clinical laboratories therefore interpret results using relevant reference information rather than assuming one ideal value for everyone. MedlinePlus: IGF-1 testing

Why clinicians measure it

IGF-1 is more stable across the day than pulsatile GH, making it useful in the evaluation of some GH-related disorders. It is not a stand-alone score for vitality, muscle potential or biological age. A result needs context, and one normal result does not answer every clinical question.

Why “higher” is not a universal target

Growth signaling must be regulated. A rise in IGF-1 after an experimental intervention establishes a biological effect, not necessarily a benefit. Researchers must determine what happened to health or function and whether the altered exposure created risks.

Similarly, the fact that IGF-1 often declines with age does not establish that raising it reverses aging. Age associations and intervention effects are different kinds of evidence.

Reading an IGF-1 claim

Ask whether the study measured circulating concentration, tissue signaling or an actual clinical outcome. Check the participants’ age and health status, the intervention and the duration. These details are necessary before interpreting a biomarker change as useful.

IGF-1 is an important part of endocrine physiology, but it should not be reduced to a number to maximize.